{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:05:00Z","timestamp":1783893900819,"version":"3.55.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40266-026-01313-w","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:19:57Z","timestamp":1782929997000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Treatment for Hyperuricemia: The Drug Pipeline"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2353-8378","authenticated-orcid":false,"given":"Austin","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-209X","authenticated-orcid":false,"given":"Lindsay N.","family":"Helget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0897-2272","authenticated-orcid":false,"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"4","key":"1313_CR1","doi-asserted-by":"publisher","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","volume":"6","author":"C Yokose","year":"2011","unstructured":"Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in prevalence of gout among US Asian adults, 2011\u20132018. JAMA Netw Open. 2011;6(4):e239501.","journal-title":"JAMA Netw Open"},{"key":"1313_CR2","doi-asserted-by":"publisher","unstructured":"O\u2019Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022;1(3). https:\/\/doi.org\/10.1056\/EVIDoa2100028","DOI":"10.1056\/EVIDoa2100028"},{"issue":"9","key":"1313_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58(9):2587\u201390.","journal-title":"Arthritis Rheum"},{"issue":"3s","key":"1313_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","volume":"50","author":"RT Keenan","year":"2020","unstructured":"Keenan RT. The biology of urate. Semin Arthritis Rheum. 2020;50(3s):S2-s10.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1313_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","volume":"78","author":"TR Merriman","year":"2011","unstructured":"Merriman TR, Dalbeth N. The genetic basis of hyperuricaemia and gout. Jt Bone Spine. 2011;78(1):35\u201340.","journal-title":"Jt Bone Spine"},{"issue":"6","key":"1313_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD Fitzgerald","year":"2020","unstructured":"Fitzgerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol"},{"key":"1313_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25618","author":"A Barry","year":"2025","unstructured":"Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, et al. Improvements in health-related quality of life with treat-to-target urate-lowering therapy in gout: a post hoc analysis of a randomized multicenter trial. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25618.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1313_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1313_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125(7):679-87.e1.","journal-title":"Am J Med"},{"issue":"3s","key":"1313_CR10","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3s):S11\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1313_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40266-021-00866-2","volume":"38","author":"M Kumar","year":"2021","unstructured":"Kumar M, Manley N, Mikuls TR. Gout flare burden, diagnosis, and management: navigating care in older patients with comorbidity. Drugs Aging. 2021;38(7):545\u201357.","journal-title":"Drugs Aging"},{"issue":"12","key":"1313_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40266-022-00986-3","volume":"39","author":"EH Kang","year":"2022","unstructured":"Kang EH. Considerations for choosing first-line urate-lowering treatment in older patients with comorbid conditions. Drugs Aging. 2022;39(12):923\u201333.","journal-title":"Drugs Aging"},{"key":"1313_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101882","volume":"41","author":"M Bortolotti","year":"2021","unstructured":"Bortolotti M, Polito L, Battelli MG, Bolognesi A. Xanthine oxidoreductase: one enzyme for multiple physiological tasks. Redox Biol. 2021;41:101882.","journal-title":"Redox Biol"},{"key":"1313_CR14","first-page":"1109","volume-title":"Firestein & Kelley\u2019s textbook of rheumatology","author":"GS Firestein","year":"2024","unstructured":"Firestein GS, McInnes IB, Koretzky G, Mikuls T, Neogi T, O\u2019Dell JR. Firestein & Kelley\u2019s textbook of rheumatology. Elsevier Health Sciences; 2024. p. 1109\u201322."},{"issue":"8","key":"1313_CR15","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1313_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/ard.40.3.245","volume":"40","author":"GT McInnes","year":"1981","unstructured":"McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40(3):245\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1313_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacrist\u00e1n JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27(3):337\u201343.","journal-title":"Ann Pharmacother"},{"issue":"23","key":"1313_CR18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"13","key":"1313_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200\u201310.","journal-title":"N Engl J Med"},{"key":"1313_CR20","unstructured":"FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat) [press release]. February 21, 2019."},{"issue":"10264","key":"1313_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745\u201357.","journal-title":"Lancet"},{"key":"1313_CR22","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.2147\/DDDT.S86884","volume":"9","author":"S Yoon","year":"2015","unstructured":"Yoon S, Shin D, Lee H, Jang IJ, Yu KS. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Dev Ther. 2015;9:5033\u201349.","journal-title":"Drug Des Dev Ther"},{"issue":"7","key":"1313_CR23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/art.42447","volume":"75","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub R, Lee J, Min J, Shin S, Saag KG. Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Arthritis Rheumatol. 2023;75(7):1275\u201384.","journal-title":"Arthritis Rheumatol"},{"key":"1313_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2025.107843","volume":"151","author":"KG Saag","year":"2025","unstructured":"Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, et al. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025;151:107843.","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"1313_CR25","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1021\/acscatal.3c01245","volume":"13","author":"Y Maghsoud","year":"2023","unstructured":"Maghsoud Y, Dong C, Cisneros GA. Computational characterization of the inhibition mechanism of xanthine oxidoreductase by topiroxostat. ACS Catal. 2023;13(9):6023\u201343.","journal-title":"ACS Catal"},{"issue":"3","key":"1313_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/jcpt.12391","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 2016;41(3):290\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"1313_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40261-020-00941-3","volume":"40","author":"T Ishikawa","year":"2020","unstructured":"Ishikawa T, Maeda T, Hashimoto T, Nakagawa T, Ichikawa K, Sato Y, et al. Long-term safety and effectiveness of the xanthine oxidoreductase inhibitor, topiroxostat in Japanese hyperuricemic patients with or without gout: a 54-week open-label, multicenter, post-marketing observational study. Clin Drug Investig. 2020;40(9):847\u201359.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1313_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jch.14153","volume":"23","author":"K Kario","year":"2021","unstructured":"Kario K, Nishizawa M, Kiuchi M, Kiyosue A, Tomita F, Ohtani H, et al. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. J Clin Hypertens (Greenwich). 2021;23(2):334\u201344.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"1313_CR29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40261-018-0699-0","volume":"38","author":"T Hosoya","year":"2018","unstructured":"Hosoya T, Ishikawa T, Ogawa Y, Sakamoto R, Ohashi T. Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese hyperuricemic patients with or without gout. Clin Drug Investig. 2018;38(12):1135\u201343.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1313_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10067-021-05956-5","volume":"41","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Okami N, Yamada T, Azushima K, Yamaji T, Kinguchi S, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):911\u20139.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"1313_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5414\/CP203478","volume":"57","author":"S Tohyo","year":"2019","unstructured":"Tohyo S. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients. Int J Clin Pharmacol Ther. 2019;57(11):567\u201370.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1313_CR32","doi-asserted-by":"publisher","unstructured":"Kydd ASR, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;2014(11):CD010457. https:\/\/doi.org\/10.1002\/14651858.CD010457.pub2.","DOI":"10.1002\/14651858.CD010457.pub2."},{"issue":"6887","key":"1313_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature"},{"issue":"2","key":"1313_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","volume":"16","author":"HJ Shin","year":"2011","unstructured":"Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011;16(2):156\u201362.","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"1313_CR35","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1124\/dmd.116.071472","volume":"44","author":"Y Tsuruya","year":"2016","unstructured":"Tsuruya Y, Kato K, Sano Y, Imamura Y, Maeda K, Kumagai Y, et al. Investigation of endogenous compounds applicable to drug\u2013drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metab Dispos. 2016;44(12):1925\u201333.","journal-title":"Drug Metab Dispos"},{"key":"1313_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf577","author":"C Dahanayake","year":"2025","unstructured":"Dahanayake C, Bajpai R, Lambie M, Jordan KM, Roddy E. Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomised controlled trials and cohort studies. Rheumatology (Oxford). 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf577.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1313_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40262-022-01121-6","volume":"61","author":"S Dubinsky","year":"2022","unstructured":"Dubinsky S, Malik P, Hajducek DM, Edginton A. Determining the effects of chronic kidney disease on organic anion transporter1\/3 activity through physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2022;61(7):997\u20131012.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1313_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","volume":"28","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging. 2011;28(8):591\u2013603.","journal-title":"Drugs Aging"},{"issue":"1","key":"1313_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1313_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"MH Lee","year":"2008","unstructured":"Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643\u201365.","journal-title":"Drug Saf"},{"issue":"12","key":"1313_CR41","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56(12):2170\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1313_CR42","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.2147\/DDDT.S119944","volume":"10","author":"M Gillen","year":"2016","unstructured":"Gillen M, Valdez S, Zhou D, Kerr B, Lee CA, Shen Z. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. Drug Des Dev Ther. 2016;10:3555\u201362.","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"1313_CR43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"D Fitz-Patrick","year":"2019","unstructured":"Fitz-Patrick D, Roberson K, Niwa K, Fujimura T, Mori K, Hall J, et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two phase II trials. Mod Rheumatol. 2019;29(6):1042\u201352.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"1313_CR44","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","volume":"57","author":"M Shiramoto","year":"2018","unstructured":"Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018;57(9):1602\u201310.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1313_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000584","volume":"4","author":"R Fleischmann","year":"2018","unstructured":"Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4(1):e000584.","journal-title":"RMD Open"},{"issue":"4","key":"1313_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.ajkd.2020.09.009","volume":"77","author":"AG Stack","year":"2021","unstructured":"Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnsson E, Erlandsson F, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021;77(4):481\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1313_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink HJL, Stack AG, Terkeltaub R, Jongs N, Inker LA, Bjursell M, et al. Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial. J Am Soc Nephrol. 2024;35(5):594\u2013606.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1313_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.119.259341","volume":"371","author":"T Taniguchi","year":"2019","unstructured":"Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371(1):162\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"1313_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020;24(Suppl 1):62\u201370.","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 1","key":"1313_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10157-020-01851-6","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24(Suppl 1):71\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"1313_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/art.43261","author":"J Sun","year":"2025","unstructured":"Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, et al. Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomized, multicenter, double\u2010blind, phase 3 trial in China. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43261.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1313_CR52","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1313_CR53","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1313_CR54","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s40001-023-01208-1","volume":"28","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Taguchi I, Hisauchi I, Yoshida H, Shimabukuro M, Hongo H, et al. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA). Eur J Med Res. 2023;28(1):238.","journal-title":"Eur J Med Res"},{"key":"1313_CR55","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/DDDT.S416025","volume":"17","author":"K Yanai","year":"2023","unstructured":"Yanai K, Hirai K, Kaneko S, Mutsuyoshi Y, Kitano T, Miyazawa H, et al. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: a single center, retrospective analysis. Drug Des Devel Ther. 2023;17:3233\u201348.","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"1313_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/jpet.115.231647","volume":"357","author":"SO Ahn","year":"2016","unstructured":"Ahn SO, Ohtomo S, Kiyokawa J, Nakagawa T, Yamane M, Lee KJ, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357(1):157\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1313_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-025-03577-w","volume":"27","author":"JB Jun","year":"2025","unstructured":"Jun JB, Lee HS, Kim SH, Lee SG, Lim DH, Kim J, et al. Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. Arthritis Res Ther. 2025;27(1):113.","journal-title":"Arthritis Res Ther"},{"key":"1313_CR58","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ard.2025.05.304","volume":"84","author":"H Ding","year":"2025","unstructured":"Ding H, Bao C, Hu J, Qian L, Yang L, Wang Z, et al. OP0302 ruzinurad for hyperuricemia associated with primary gout: a multicenter, randomized, double-blind, active-controlled, phase 3 study. Ann Rheum Dis. 2025;84:240\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1313_CR59","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021;60(11):5089\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"1313_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211067304","volume":"14","author":"H Tang","year":"2022","unstructured":"Tang H, Cui B, Chen Y, Chen L, Wang Z, Zhang N, et al. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study. Ther Adv Musculoskelet Dis. 2022;14:1759720x211067304.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1313_CR61","unstructured":"Yan R, Zhu N, Shen Z, Yan S, Yeh L. AR882, a potent and selective URAT1 inhibitor with a favorable pharmacological, pharmacokinetic and toxicity profile [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). Abstract 1229."},{"key":"1313_CR62","unstructured":"Wei JC-C, Fleischmann R, Morris S, Hingorani V, Polvent E, Shen Z, et al. Efficacy and safety of AR882, a selective uric acid transporter 1 (URAT1) inhibitor, in gout patients with various baseline characteristics following 12-week treatment in patients [abstract]. Arthritis Rheumatol. 2023;75(suppl 9) https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-ar882-a-selective-uric-acid-transporter-1-urat1-inhibitor-in-gout-patients-with-various-baseline-characteristics-following-12-week-treatment-in-patients\/. Accessed\u00a09 June 2026."},{"issue":"Suppl 1","key":"1313_CR63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/annrheumdis-2024-eular.3659","volume":"83","author":"R Keenan","year":"2024","unstructured":"Keenan R, Wei J, Dalbeth N, Morris S, Mundell P, Wei W, et al. POS0268 AR882, a novel and selective URAT1 inhibitor, significantly reduced tophi in patients with chronic gouty arthritis: results of 12-month outcome from a global trial using digital caliper measurements and dual energy computed tomography. Ann Rheum Dis. 2024;83(Suppl 1):409.","journal-title":"Ann Rheum Dis"},{"key":"1313_CR64","volume-title":"A double-blind, placebo-controlled, ascending dose phase 2a study of ABP-671, a novel, potent and selective URAT1 inhibitor, in patients with gout or hyperuricemia. Arthritis and rheumatology","year":"2022","unstructured":"Gurwith M, Smith D, Bird P, Leung J, Bloch M, Kim J, et al editors. A double-blind, placebo-controlled, ascending dose phase 2a study of ABP-671, a novel, potent and selective URAT1 inhibitor, in patients with gout or hyperuricemia. Arthritis and rheumatology. USA: Wiley; 2022."},{"key":"1313_CR65","unstructured":"Atom therapeutics announces positive topline results of lingdolinurad (ABP-671) in phase 2b\/3 trial for chronic gout [press release]. 2025. https:\/\/atomthera.us\/2025\/09\/07\/atom-announces-positive-topline-results-of-lingdolinurad-in-phase-2b-3-trial-for-gout\/. Accessed 9 June 2026."},{"issue":"9","key":"1313_CR66","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, Dillon A, V\u00e1zquez-Mellado J, Ottery FD, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72(9):1469\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1313_CR67","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1313_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","volume":"17","author":"V Strand","year":"2021","unstructured":"Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021;17(2):81\u201397.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1313_CR69","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1097\/RHU.0000000000001639","volume":"28","author":"JK Botson","year":"2022","unstructured":"Botson JK, Peterson J. Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series. J Clin Rheumatol. 2022;28(1):e129\u201334.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"1313_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.42335","volume":"75","author":"JK Botson","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75(2):293\u2013304.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1313_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"1\u20132","key":"1313_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2009.11.034","volume":"387","author":"S Freitas Dda","year":"2010","unstructured":"Freitas Dda S, Spencer PJ, Vass\u00e3o RC, Abrah\u00e3o-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm. 2010;387(1\u20132):215\u201322.","journal-title":"Int J Pharm"},{"key":"1313_CR73","first-page":"abstract 1218","volume":"71","author":"R Azeem","year":"2019","unstructured":"Azeem R, Park J, Plotkin H, Kivitz A, Johnston L, Kishimoto TK, et al. Monthly dosing of ImmTOR tolerogenic nanoparticles combined with pegylated uricase (pegadricase) enables sustained reduction of acute gout flares in symptomatic gout patients. Arthritis Rheumatol. 2019;71:abstract 1218.","journal-title":"Arthritis Rheumatol"},{"key":"1313_CR74","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","volume":"11","author":"TK Kishimoto","year":"2020","unstructured":"Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front Immunol. 2020;11:969.","journal-title":"Front Immunol"},{"issue":"1","key":"1313_CR75","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41467-021-27945-7","volume":"13","author":"E Sands","year":"2022","unstructured":"Sands E, Kivitz A, DeHaan W, Leung SS, Johnston L, Kishimoto TK. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat Commun. 2022;13(1):272.","journal-title":"Nat Commun"},{"issue":"4","key":"1313_CR76","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/rheumatology\/kead333","volume":"63","author":"HSB Baraf","year":"2024","unstructured":"Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, et al. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR\u2122) versus pegloticase for refractory gout. Rheumatology (Oxford). 2024;63(4):1058\u201367.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"1313_CR77","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/annrheumdis-2023-eular.7084","volume":"82","author":"HSB Baraf","year":"2023","unstructured":"Baraf HSB, Kivitz A, Rhodes S, Leung S, Folarin O, Gonzalez-Rivera T, et al. LB0002 safety and efficacy of SEL-212 in patients with gout refractory to coventional treatment: outcomes from two randomized, double blind, placebo-controlled, multicenter phase III studies. Ann Rheum Dis. 2023;82(Suppl 1):200\u20131.","journal-title":"Ann Rheum Dis"},{"key":"1313_CR78","unstructured":"Gaffo A BH, Patel A, Neogi T, Azeem R, DeHaan W, Peace B, Santin-Janin H, Desai B, Schlesinger N. Nanoencapsulated sirolimus plus pegadricase (NASP) demonstrates a reduction in gout flares: results from the phase 3 DISSOLVE studies [abstract]. Arthritis Rheumatol. 2025;77(suppl 9). Abstract 2588."},{"key":"1313_CR79","doi-asserted-by":"crossref","unstructured":"Baraf HSB, Schlesinger N, Strand V. Nanoencapsulated sirolimus plus pegadricase (NASP) in uncontrolled gout: current status and future directions. Drugs. 2026;86(3):273\u2013285. doi:10.1007\/s40265-025-02267-w.","DOI":"10.1007\/s40265-025-02267-w"},{"key":"1313_CR80","unstructured":"Khanna P MA, Azeem R, Peace B, Desai B, Strand V. Nanoencapsulated sirolimus plus pegadricase reduced disease burden in patients with uncontrolled gout: results from the phase 3 DISSOLVE trials [abstract]. Arthritis Rheumatol. 2025;77(suppl 9)."},{"key":"1313_CR81","unstructured":"Schwabe C CBO, Cole A, Reuveni H, Shelev L, Blinder-Haddad L, Dalbeth N. Prolonged plasma urate-lowering after a single intravenous administration of PRX-115, a novel PEGylated uricase, in participants with elevated urate levels [abstract]. Arthritis Rheumatol. 2024;76(suppl 9)."},{"issue":"11","key":"1313_CR82","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"7081","key":"1313_CR83","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341.","journal-title":"Nature"},{"issue":"1","key":"1313_CR84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12967-025-06072-7","volume":"23","author":"Y Xue","year":"2025","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, et al. Firsekibart in acute gouty arthritis. J Transl Med. 2025;23(1):91.","journal-title":"J Transl Med"},{"key":"1313_CR85","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ard.2025.06.527","volume":"84","author":"Y Xue","year":"2025","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, et al. POS1177 efficacy and safety of firsekibart in acute gouty arthritis: a multicentre, randomized, double-blind, double-dummy, active-controlled phase III study. Ann Rheum Dis. 2025;84:1246\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1313_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.70030","volume":"15","author":"X Yong","year":"2026","unstructured":"Yong X, Du X, Li X, Chen Y, Zhu X, Luo T, et al. A randomized, double-blind, placebo-controlled, multiple ascending dose phase 1 study of firsekibart in Chinese healthy participants. Clin Pharmacol Drug Dev. 2026;15(2):e70030.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"11","key":"1313_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70111","volume":"7","author":"Y Yu","year":"2025","unstructured":"Yu Y, Xue Y, Hu J, Zhang N, Li R, Guo H, et al. Firsekibart as a prophylactic treatment for acute gout flare in participants initiating urate-lowering therapy: a phase 2, randomized, open-label, multicenter, active-controlled trial. ACR Open Rheumatol. 2025;7(11):e70111.","journal-title":"ACR Open Rheumatol."},{"issue":"7","key":"1313_CR88","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA. 2018;115(7):E1530\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1313_CR89","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"V Kl\u00fcck","year":"2020","unstructured":"Kl\u00fcck V, Jansen T, Janssen M, Comarniceanu A, Efd\u00e9 M, Tengesdal IW, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2(5):e270\u201380.","journal-title":"Lancet Rheumatol."},{"key":"1313_CR90","volume":"85","author":"Y Xue","year":"2026","unstructured":"Xue Y, Zou H, Zhao S, Hu J, Liu J, Jiang C, et al. Efficacy and safety of HR091506 extended-release tablets in patients with gout, hyperuricemia, and recurrent flares, tophi, or chronic gouty arthropathy: a multicenter, randomized, double-blind phase 3 trial [abstract]. Ann Rheum Dis. 2026;85:s310.","journal-title":"Ann Rheum Dis"},{"key":"1313_CR91","unstructured":"Arthrosi therapeutics receives FDA fast track designation for AR882 in tophaceous gout [press release]. 2024. https:\/\/arthrosi.com\/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout\/. Accessed 9 June 2026."},{"issue":"Suppl 1","key":"1313_CR92","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2024-eular.1697","volume":"83","author":"H Zou","year":"2024","unstructured":"Zou H, Xue Y, Zhou Q, Xu Y, Huang H. AB0190 SSGJ-613 relieves pain and reduces the risk of acute flares in patients with gout: results of a randomized, double-blind, phase II study. Ann Rheum Dis. 2024;83(Suppl 1):1330.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01313-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:01:23Z","timestamp":1783893683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01313-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01313-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TRM has received previous research funding from Horizon Therapeutics (Amgen) and has served as a consultant for Horizon, UCB, Merck, and Olatec Therapeutics. AB and LNH have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AB, TRM, and LNH participated in drafting the manuscript and have all read and approved the final submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}